Lucia Masarova, M.D.

Peer-Reviewed Articles

1. Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
2. Fiskus W, Masarova L, Mill CP, Birdwell C, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Manshouri T, Dunbar A, Sharma S, Kadia TM, DiNardo CD, Bose P, Pemmaraju N, Loghavi S, Su X, Rampal RK, Torngren M, Bhalla KN. Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase. Blood Adv, 2025. e-Pub 2025. PMID: 40829105.
3. Reeves BN, Masarova L, Abu-Zeinah G, Hunter AM, Shatzel JJ, Qin A, Yoon CH, Cai LY, Wei YF, Mesa RA. A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database. Ann Hematol 104(7):3669-3679, 2025. e-Pub 2025. PMID: 40637862.
4. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110(7):1628-1633, 2025. e-Pub 2025. PMID: 39973365.
5. Masarova L, Verstovsek S, Palandri F, Mesa R, Harrison C, Sajeev G, Gorsh B, Simpson R, Cho S, Wang Z, Ellis C, Conlon S, Signorovitch J. Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis. Future Oncol 21(16):2077-2087, 2025. e-Pub 2025. PMID: 40476514.
6. Masarova L, Verstovsek S, Palandri F, Mesa R, Harrison C, Dobi B, Gorsh B, Wang Z, Ellis C, Patnaik D, Liu T, Kapetanakis V. Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis. Future Oncol 21(16):2067-2075, 2025. e-Pub 2025. PMID: 40476686.
7. Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, Kadia, TM, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, N, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research 153, 2025. e-Pub 2025. PMID: 40252309.
8. Vachhani P, Tan P, Watson AM, Wu SJ, Baker R, Cheung S, Lee SE, Chen CC, Chen TY, Hsiao HH, Lee JH, Masarova L, Tan SY, Baskar J, Charlton B, Findlay A, Hamprecht D, Jarolimek W, Leadbetter J, Miller J, Morgan K, Zahoor A, Hobbs G. A phase I / IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis. Haematologica, 2025. e-Pub 2025. PMID: 40241543.
9. DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
10. Mascarenhas J, Bose P, Hillis C, Yacoub A, El Chaer F, Maze D, Abu-Zeinah G, Qin A, Priego V, Tashi T, Cerquozzi S, Babu S, Foltz L, Goel S, Bhave RR, Lee S, Oh ST, Reeves B, Benton C, Fletcher L, Sirhan S, Safah H, Salib H, Villeneuve PJA, Zagrijtschuk O, Castro H, Masarova L. ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera. Acta Haematol:1-7, 2025. e-Pub 2025. PMID: 40043697.
11. Bewersdorf JP, Mi X, Lu B, Kuykendall A, Sallman D, Patel M, Stevens D, Philipovskiy A, Sutamtewagul G, Masarova L, Keiffer G, Verma A, Bhagwat N, Wang M, Moore A, Rager J, Heiser D, Ro S, Hong WJ, Abdel-Wahab O, Stein EM. Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies. Leukemia 39(3):765-769, 2025. e-Pub 2025. PMID: 39856223.
12. Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
13. Masarova L, Reeves BN, El Chaer F, Foltz L, Tashi T, Abu-Zeinah G, Lucas J, Halpern AB, Maze D, Qin A, Safah H, Lan F, O'Connell CL, Goel S, Rein L, Fang B, How J, Babu S, Li Z, Cerquozzi S, Oh ST, Hunter AM, Podoltsev N, Vachhani P, Yacoub A, Cunningham JM, Hillis C, Otoukesh S, Zagrijtschuk O, Castro H, Bose P. A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial. Front Med (Lausanne) 12:1548590, 2025. e-Pub 2025. PMID: 40330782.
14. Masarova L, Liu T, Fillbrunn M, Li W, Sajeev G, Rao S, Gorsh B, Signorovitch J. Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials. Cancers (Basel) 16(23), 2024. e-Pub 2024. PMID: 39682253.
15. Masarova, L, Liu, T, Fillbrunn, M, Li, W, Sajeev, G, Rao, S, Gorsh, B, Signorovitch, JE. Transfusion-Related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Momelotinib in the SIMPLIFY-1 and SIMPLIFY-2 Trials. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682253.
16. Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 39548557.
17. Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell C, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores L, Loghavi S, DiNardo CD, Su X, Rampal RK, Bhalla KN. Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood 145(6):612-624, 2024. e-Pub 2024. PMID: 39561280.
18. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39(2):524-528, 2024. e-Pub 2024. PMID: 39551874.
19. Tefferi, A, Barosi, G, Passamonti, F, Hernández-Boluda, JC, Bose, P, Döhner, K, Ellis, M, Gangat, N, Garcia, JS, Gisslinger, H, Gotlib, J, Guglielmelli, P, Gupta, V, Harrison, C, Hexner, E, Hobbs, GS, Kiladjian, JJ, Koschmieder, S, Kröger, N, Kuykendall, A, Loscocco, GG, Mascarenhas, J, Masarova, L, Mesa, RA, Mora, B, Odenike, O, Oh, ST, Pardanani, A, Patel, A, Pemmaraju, N, Rambaldi, A, Rampal, R, Sirhan, S, Szuber, N, Talpaz, M, Vachhani, P, Vannucchi, AM, Barbui, T. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis. Blood 144(17):1813-1820, 2024. e-Pub 2024. PMID: 39116296.
20. Masarova L, Chifotides HT Dr. How I individualize selection of JAK inhibitors for patients with myelofibrosis. Blood 145(16):1724-1737, 2024. e-Pub 2024. PMID: 39357058.
21. Huang, M, Ke, Z, Lyu, M, Masarova, L, Sadeghi, T, Flowers, CR, Parmar, S. CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation. iScience 27(9), 2024. e-Pub 2024. PMID: 39314243.
22. Huang M, Ke Z, Lyu MA, Masarova L, Sadeghi T, Flowers CR, Parmar S. CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation. iScience 27(9):110830, 2024. e-Pub 2024. PMID: 39314243.
23. Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
24. Goulart H, Masarova L, Mesa R, Harrison C, Kiladjian J, Pemmaraju N. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature. BJHaem 205(1):48-60, 2024. e-Pub 2024.
25. Kadia TM, Huang M, Pemmaraju N, Abbas HA, Ly C, Masarova L, Yilmaz M, Lyu MA, Zeng K, Sadeghi T, Cook R, DiNardo CD, Daver N, Issa GC, Jabbour E, Borthakur G, Jain N, Garcia-Manero G, Parmar S, Flowers C, Kantarjian H, Verstovsek S. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid 3(6):EVIDoa2300362, 2024. e-Pub 2024. PMID: 38804782.
26. Gotlib J, Gerds AT, Abdelmessieh P, Ali H, Castells M, Dunbar A, Fein Revell R, George TI, Green S, Gundabolu K, Hexner E, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, Manchanda N, Masarova L, May J, McMahon B, Mohan SR, Nadiminti KV, Oh S, Palmer J, Patel A, Patel AA, Podoltsev N, Rein L, Salit R, Talpaz M, Wadleigh M, Wall S, Bergman MA, Hochstetler C. NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024. J Natl Compr Canc Netw 22(2D), 2024. e-Pub 2024. PMID: 38862005.
27. Nasnas PE, Jabbour EJ, Sasaki K, Issa GC, Masarova L, Short NJ, Haddad FG. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia. Acta Haematol 148(1):105-110, 2024. e-Pub 2024. PMID: 38574468.
28. Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
29. Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
30. Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
31. Masarova L, Verstovsek S, Liu T, Rao S, Sajeev G, Fillbrunn M, Simpson R, Li W, Yang J, Le Lorier Y, Gorsh B, Signorovitch J. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM. Future Oncol 20(30):2259-2270, 2024. e-Pub 2024. PMID: 39072442.
32. Jurikova L, Masarova L, Panovsky R, Pesl M, Revendova KZ, Volny O, Feitova V, Holecek T, Kincl V, Danhofer P, Vohanka S, Haberlova J, Podolska K. Decreased quality of life in Duchenne muscular disease patients related to functional neurological and cardiac impairment. Front Neurol 15:1360385, 2024. e-Pub 2024. PMID: 38390598.
33. Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
34. Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce S, Estrov Z, Kantarjian H, Verstovsek S. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years. Acta Haematol 146(6):522-529, 2023. e-Pub 2023. PMID: 37699357.
35. Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
36. Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
37. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
38. Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, Turkalj S, Jakobsen NA, Luskin MR, Duose DY, Tidwell RSS, Short NJ, Borthakur G, Kadia TM, Masarova L, Tippett GD, Bose P, Jabbour EJ, Ravandi F, Daver NG, Garcia-Manero G, Kantarjian H, Garcia JS, Vyas P, Takahashi K, Konopleva M, DiNardo CD. A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov 4(4):276-293, 2023. e-Pub 2023. PMID: 37102976.
39. DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
40. Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029, 2023. e-Pub 2023. PMID: 36715486.
41. Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
42. Al-Ghamdi YA, Lake J, Bagg A, Thakral B, Wang SA, Bueso-Ramos C, Masarova L, Verstovsek S, Rogers HJ, Hsi ED, Gralewski JH, Chabot-Richards D, George TI, Rets A, Hasserjian RP, Weinberg OK, Parilla M, Arber DA, Padilla O, Orazi A, Tam W. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol 36(3):100016, 2023. e-Pub 2023. PMID: 36788093.
43. Babakhanlou R, Masarova L, Verstovsek S. A review of essential thrombocythemia and its complications. Clin Adv Hematol Oncol 21(2):76-84, 2023. e-Pub 2023. PMID: 36780473.
44. Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose P. Impact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma 63(11):1-5, 2022. e-Pub 2022. PMID: 35787095.
45. Abuasab, T, Alvarado, Y, Issa, GC, Islam, R, James, N, Yilmaz, M, Jain, N, Masarova, L, Kornblau, SM, Jabbour, EJ, Pemmaraju, N, Montalban Bravo, G, Pierce, S, DiNardo, C, Kadia, TM, Daver, N, Konopleva, M, Garcia-Manero, G, Ravandi-Kashani, F. AML-328 Phase 2 Study of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Previously Untreated, Older Adult Patients Unfit for Chemotherapy. Clinical Lymphoma, Myeloma and Leukemia 22:S237, 2022. e-Pub 2022. PMID: 36163813.
46. Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, TM, Masarova, L, Takahashi, K, Tippett, G, Garcia, JS, Bose, P, Jabbour, EJ, Ravandi-Kashani, F, Daver, N, Garcia-Manero, G, Vyas, P, Kantarjian, HM, Konopleva, M, DiNardo, C. AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S240-S241, 2022. e-Pub 2022. PMID: 36163821.
47. Bazinet A, Darbaniyan F, Jabbour E, Montalban-Bravo G, Ohanian M, Chien K, Kadia T, Takahashi K, Masarova L, Short N, Alvarado Y, Yilmaz M, Ravandi F, Andreeff M, Kanagal-Shamanna R, Ganan-Gomez I, Colla S, Qiao W, Huang X, McCue D, Mirabella B, Kantarjian H, Garcia-Manero G. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 9(10):e756-e765, 2022. e-Pub 2022. PMID: 36063832.
48. Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334, 2022. e-Pub 2022. PMID: 36164003.
49. Masarova L. EXABS-116-MPN Extended Abstract: Novel Therapies for PV. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S18-S20, 2022. e-Pub 2022. PMID: 36163714.
50. Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S334-S335, 2022. e-Pub 2022. PMID: 36164004.
51. Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
52. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
53. Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
54. Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
55. Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S, Short NJ, Ohanian M, Masarova L, Issa G, Wang X, Carlos BR, Yilmaz M, Kadia T, Andreeff M, Ravandi F, Konopleva M, Kantarjian HM, DiNardo CD. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12(1):10, 2022. e-Pub 2022. PMID: 35078972.
56. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2022. PMID: 34716921.
57. Abou Dalle I, Kantarjian H, Daver N, Masarova L, Pemmaraju N, Bose P, Garcia-Manero G, Verstovsek S. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol 100(12):2957-2960, 2021. e-Pub 2021. PMID: 34350483.
58. Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica Online ahead of print(11):2853-2858, 2021. e-Pub 2021. PMID: 33054123.
59. Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
60. DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):JCO2003736, 2021. e-Pub 2021. PMID: 34043428.
61. Pemmaraju N, Carter BZ, Bose P, Jain N, Kadia TM, Garcia-Manero G, Bueso-Ramos CE, DiNardo CD, Bledsoe S, Daver NG, Popat U, Konopleva MY, Zhou L, Pierce S, Estrov ZE, Borthakur GM, Ohanian M, Qiao W, Masarova L, Wang X, Mak PY, Cortes J, Jabbour E, Verstovsek S. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv 5(16):3163-3173, 2021. e-Pub 2021. PMID: 34424319.
62. Bose P, McCue D, Wurster S, Wiederhold NP, Konopleva M, Kadia TM, Borthakur G, Ravandi F, Masarova L, Takahashi K, Estrov Z, Yilmaz M, Daver N, Pemmaraju N, Naqvi K, Rausch CR, Marx KR, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. Clin Infect Dis 72(10):1755-1763, 2021. e-Pub 2021. PMID: 32236406.
63. Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 11(5):98, 2021. e-Pub 2021. PMID: 34016956.
64. Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, Kantarjian H, Estrov Z, Verstovsek S. Clinical Significance of Bone Marrow Blast Percentage in Patients with Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk 21(5):318-327.e6, 2021. e-Pub 2021. PMID: 33551345.
65. Davila-Gonzalez D, Barrios-Ruiz A, Fountain E, Cheng L, Masarova L, Verstovsek S, Rojas-Hernandez CM. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk 21(4):224-229, 2021. e-Pub 2021. PMID: 33349602.
66. Masarova L, DiNardo CD, Bose P, Pemmaraju N, Daver NG, Kadia TM, Chifotides HT, Zhou L, Borthakur G, Estrov Z, Konopleva M, Verstovsek S. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv 5(8):2156-2164, 2021. e-Pub 2021. PMID: 33885751.
67. Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol 96(3):1-10, 2021. e-Pub 2021. PMID: 33264443.
68. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
69. Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal‐Shamanna R, Cortes J, Samra B, Jabbour E, Garcia‐Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021.
70. Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
71. Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek S. Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv 4(21):5336-5342, 2020. e-Pub 2020. PMID: 33112940.
72. Paul S, Jammal N, Akhave N, Aung PP, Loghavi S, Jain N, Garcia-Manero G, Borthakur G, Verstovsek S, Jabbour E, Adachi J, Masarova L, Daver N, Ravandi F, Pemmaraju N. Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. Br J Haematol 191(1):e10-e13, 2020. e-Pub 2020. PMID: 32686139.
73. Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126(19):4322-4331, 2020. e-Pub 2020. PMID: 32697338.
74. DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
75. Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia 34(9):2489-2492, 2020. e-Pub 2020. PMID: 32099037.
76. Gowin K, Ballen K, Ahn KW, Hu ZH, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, Gupta V, Hobbs G, Jain T, Kandarpa M, Komrokji R, Kuykendall AT, Luber K, Masarova L, Michaelis LC, Patches S, Pariser AC, Rampal R, Stein B, Talpaz M, Verstovsek S, Wadleigh M, Agrawal V, Aljurf M, Angel Diaz M, Avalos BR, Bacher U, Bashey A, Beitinjaneh AM, Cerny J, Chhabra S, Copelan E, Cutler CS, DeFilipp Z, Gadalla SM, Ganguly S, Grunwald MR, Hashmi SK, Kharfan-Dabaja MA, Kindwall-Keller T, Kröger N, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Nathan S, Nishihori T, Olsson RF, Pawarode A, Rowe JM, Savani BN, Savoie ML, Seo S, Solh M, Tamari R, Verdonck LF, Yared JA, Alyea E, Popat U, Sobecks R, Scott BL, Nakamura R, Mesa R, Saber W. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv 4(9):1965-1973, 2020. e-Pub 2020. PMID: 32384540.
77. Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HM. Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer 126(7):1448-1459, 2020. e-Pub 2020. PMID: 31999850.
78. Saenz DT, Fiskus W, Mill CP, Perera D, Manshouri T, Lara BH, Karkhanis V, Sharma S, Horrigan SK, Bose P, Kadia TM, Masarova L, DiNardo CD, Borthakur G, Khoury JD, Takahashi K, Bhaskara S, Lin CY, Green MR, Coarfa C, Crews CM, Verstovsek S, Bhalla KN. Mechanistic basis and efficacy of targeting β-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors. Blood 135(15):1255-1269, 2020. e-Pub 2020. PMID: 32068780.
79. Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-González GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HM. Long-Term Results of Frontline Dasatinib in Chronic Myeloid Leukemia. Cancer 126(7):1-12, 2020. e-Pub 2020. PMID: 31999839.
80. Masarova L, Mesa RA, Hernández-Boluda JC, Taylor JA. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. Leuk Res 91:106338, 2020. e-Pub 2020. PMID: 32200188.
81. Santos FPS, Getta B, Masarova L, Famulare C, Schulman J, Datoguia TS, Puga RD, Alves Paiva RM, Arcila ME, Hamerschlak N, Kantarjian HM, Levine RL, Campregher PV, Rampal RK, Verstovsek S. Prognostic impact of RAS-pathway mutations in patients with myelofibrosis. Leukemia 34(3):799-810, 2020. e-Pub 2020. PMID: 31628430.
82. Masarova L, Cortes J, Patel K, O’Brien S, Nogueras-Gonzalez G, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia T, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour E, Kantarjian H. Long-Term Results of a Phase 2 Trial of Nilotinib 400 mg Twice Daily in Newly Diagnosed Patients With Chronic-Phase Chronic Myeloid Leukemia. Cancer:1-10, 2020. e-Pub 2020.
83. Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):1-7, 2020. e-Pub 2020. PMID: 32289808.
84. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
85. Saenz DT, Fiskus W, Manshouri T, Mill CP, Qian Y, Raina K, Rajapakshe K, Coarfa C, Soldi R, Bose P, Borthakur G, Kadia TM, Khoury JD, Masarova L, Nowak AJ, Sun B, Saenz DN, Kornblau SM, Horrigan S, Sharma S, Qiu P, Crews CM, Verstovsek S, Bhalla KN. Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia 33(6):1373-1386, 2019. e-Pub 2019. PMID: 30575820.
86. Masarova L, Verstovsek S. Emerging drugs for essential thrombocythemia. Expert Opin Emerg Drugs 24(2):1-13, 2019. e-Pub 2019. PMID: 31050912.
87. Masarova L, Verstovsek S. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis. Clin Adv Hematol Oncol 17(5):299-307, 2019. e-Pub 2019. PMID: 31188809.
88. Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek S. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133(21):2348-2351, 2019. e-Pub 2019. PMID: 30796023.
89. Fiskus W, Cai T, DiNardo CD, Kornblau SM, Borthakur G, Kadia TM, Pemmaraju N, Bose P, Masarova L, Rajapakshe K, Perera D, Coarfa C, Mill CP, Saenz DT, Saenz DN, Sun B, Khoury JD, Shen Y, Konopleva M, Bhalla KN. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J 9(2):4, 2019. e-Pub 2019. PMID: 30647404.
90. Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol 97(11):2071-2080, 2018. e-Pub 2018. PMID: 29951914.
91. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132(16):1664-1674, 2018. e-Pub 2018. PMID: 30185431.
92. Masarova L, Alhuraiji A, Bose P, Daver N, Pemmaraju N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Significance of thrombocytopenia in patients with primary and post essential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol 100(3):257-263, 2018. e-Pub 2018. PMID: 29226426.
93. Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109-121, 2018. e-Pub 2018. PMID: 29143068.
94. Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130(9):1125-1131, 2017. e-Pub 2017. PMID: 28674026.
95. Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res 59:110-116, 2017. e-Pub 2017. PMID: 28601551.
96. Strati P, Masarova L, Bose P, Daver N, Pemmaraju N, Verstovsek S. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res 57:85-88, 2017. e-Pub 2017. PMID: 28324773.
97. Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S. Therapy-related myelofibrosis does not appear to exist. Blood Adv 1(14):863-866, 2017. e-Pub 2017. PMID: 29296729.
98. Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol 4(4):e165-e175, 2017. e-Pub 2017. PMID: 28291640.
99. Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Exp Hematol Oncol 6:30, 2017. e-Pub 2017. PMID: 29152412.
100. Masarova L, Kantarjian H, Daver N. Immune Checkpoint Approaches in AML and MDS: A Next Frontier?. The Journal of Targeted Therapies in Cancer 10:903-914, 2017. e-Pub 2017.
101. Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leuk Res 48:1-5, 2016. e-Pub 2016. PMID: 27416326.
102. Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma 57(5):1054-9, 2016. e-Pub 2016. PMID: 26402369.
103. Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma 57(1):237-9, 2016. e-Pub 2016. PMID: 25904378.
104. Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S. Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome. Leuk Res 39(8):822-7, 2015. e-Pub 2015. PMID: 26012362.
105. Racil Z, Toskova M, Kocmanova I, Buresova L, Kouba M, Drgona L, Masarova L, Guman T, Tothova E, Gabzdilova J, Forsterova K, Haber J, Ziakova B, Bojtarova E, Rolencova M, Timilsina S, Cetkovsky P, Mayer J. Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. Leuk Lymphoma 54(5):1042-7, 2013. e-Pub 2013. PMID: 23088794.
106. Racil Z, Weinbergerova B, Kocmanova I, Muzik J, Kouba M, Drgona L, Masarova L, Guman T, Tothova E, Forsterova K, Haber J, Ziakova B, Bojtarova E, Vydra J, Mudry P, Foralova R, Sejnova D, Mallatova N, Kandrnal V, Cetkovsky P, Mayer J. Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal Infection Database (FIND) analysis, 2005-2009. Int J Infect Dis 17(2):e101-9, 2013. e-Pub 2013. PMID: 23084969.
107. Drgona L, Mallatova N, Masarova L, Michalkova J, Guman T, et al. Multicenter observational study on hematological patients with the failure of the first line antifungal treatment for invasive aspergillosis (OSPIA). Mycoses:52-54, 2011. e-Pub 2011.

Invited Articles

1. Masarova L, Verstovsek S. Therapeutic Approach to Young Patients With Low-Risk Essential Thrombocythemia: Primum Non Nocere. J Clin Oncol:JCO2018793497. e-Pub 2018. PMID: 30346901.

Review Articles

1. Masarova, L, Mascarenhas, J, Rampal, R, Hu, W, Livingston, RA, Pemmaraju, N. Ten years of experience with ruxolitinib since approval for polycythemia vera. Cancer 131(1), 2025. e-Pub 2025. PMID: 39616447.
2. Mughal TI, Mascarenhas J, Rampal RK, Bose P, Lion T, Ajufo H, Yacoub A, Meshinchi S, Masarova L, Mesa R, Jamieson C, Barbui T, Saglio G, Van Etten RA. Impact of Recent Translational and Therapeutic Developments on Clinical Course of BCR::ABL1-Positive and -Negative Myeloproliferative Neoplasms. Hematol Oncol 43(1):e70013, 2025. e-Pub 2025. PMID: 39825826.
3. Goulart, H, Masarova, L, Mesa, RA, Harrison, C, Kiladjian, JJ, Pemmaraju, N. Myeloproliferative neoplasms in the adolescent and young adult population. British Journal of Haematology 205(1):48-60, 2024. e-Pub 2024. PMID: 38853641.
4. Patel AB, Masarova L, Mesa RA, Hobbs G, Pemmaraju N. Polycythemia vera: past, present and future. Leuk Lymphoma:1-13. e-Pub 2024. PMID: 38871488.
5. Opatril L, Panovsky R, Mojica-Pisciotti M, Krejci J, Masarova L, Kincl V, Rehorkova M, Spinarova L. Stress and Rest Pulmonary Transit Times Assessed by Cardiovascular Magnetic Resonance. Cardiol Rev 32(3):243-247, 2024. e-Pub 2024. PMID: 36728820.
6. Masarova L, Chifotides HT. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera. Clin Lymphoma Myeloma Leuk 24(3):141-148, 2024. e-Pub 2024. PMID: 38135633.
7. Vachhani P, Mascarenhas J, Bose P, Hobbs G, Yacoub A, Palmer JM, Gerds AT, Masarova L, Kuykendall AT, Rampal RK, Mesa R, Verstovsek S. Interferons in the treatment of myeloproliferative neoplasms. Ther Adv Hematol 15:20406207241229588, 2024. e-Pub 2024. PMID: 38380373.
8. Chifotides HT, Masarova L, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 23(4):219-231, 2023. e-Pub 2023. PMID: 36797153.
9. Chifotides HT, Bose P, Masarova L, Pemmaraju N, Verstovsek S. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clin Lymphoma Myeloma Leuk 22(4):210-223, 2022. e-Pub 2022. PMID: 34840087.
10. Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematol 144(5):1-16, 2021. e-Pub 2021. PMID: 33882481.
11. Bose P, Masarova L, Verstovsek S. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050168.
12. Masarova L, Bose P, Verstovsek S. The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep 14(4):310-327, 2019. e-Pub 2019. PMID: 31228096.
13. Bose P, Masarova L, Verstovsek S. Novel treatment strategies for myeloproliferative neoplasms. Rinsho Ketsueki 60(9):1176-1185, 2019. e-Pub 2019. PMID: 31597841.
14. Masarova L, Verstovsek S, Kantarjian H, Daver N. Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol 10(10):903-914, 2017. e-Pub 2017. PMID: 28799436.
15. Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95, 2017. e-Pub 2017. PMID: 28321813.

Professional Educational Materials

1. Racil Z, Weinbergerova B, Drgona L, Masarova L. Empirical and preemptive antimycotic therapy in patients with haematooncologic malignancies. Postgraduální medicína, 2016.
2. Masarova L, Mego M. Biological treatment in oncology. Via practica, 2011.
3. Masarova L, Mego M. Use of biological therapy in clinical oncology, 2011.
4. Masarova L. Treatment of invasive fungal diseases - 3rd Fungal Forum. Onkologia, 2010.

Other Articles

1. Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, Rampal RK Moving towards disease modification in polycythemia vera. Blood 142(22):1859-1870, 2023. PMID: 37729609.
2. Masarova L Momelotinib, the next JAK2 inhibitor?. Clin Adv Hematol Oncol 21(4):195-197, 2023. PMID: 37039727.
3. Masarova L Mego M Biological treatment in oncology. Via practica(8):265-269, 2011.
4. Masarova L, Mego M Use of biological therapy in clinical oncology. Bedeker Zdravia 3, 2011.
5. Masarova L 3rd Fungal Forum. Treatment of invasive fungal diseases. Onkologia 5:304-305, 2010.

Abstracts

1. Masarova L, Verstovsek S, Liu, Rao S, Sajeev G, Simpson S, Li W, Yang J, Gorsh B, Signorovitch J. Transfusion-related costs offsets and time burden in patients with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN). EHA Library 387289(PB2183), 2023. e-Pub 2023.
2. Masarova L, Verstovsek S, Palandri F, Mesa R, Harrison C, Dobi B, Gorsh B, Wang Z, Ellis C, Patnaik D, Kapetanakis V. Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis. (Abstract release date: 05/11/23). EHA Library(385507):P1057, 2023. e-Pub 2023.
3. Masarova L, Mascarenhas J, Qin A, Shih W, Sato T, Urbanski R, Zagrijtschuk O, Zimmerman C. EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia. Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
4. Masarova L, Verstovsek S, Palandri F, Mesa AR, Harrison C, Sajeev G, Gorsh B, Simpson R, Cho KS, Wang Z, Ellis EC, Conlon S. Signorovitch J. Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF). Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
5. Masarova L, Huang M, Kadia MT, Pemmaraju N, Daver GN, M-A L, Zeng K, Sadeghi T, Asatiani E, Parmar S, Flowers C, Verstovsek S. Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib. Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
6. Nasr LF, Jabbour JE, Haddad F, Short NJ, Macaron W, Nasnas CC, Zoghbi M, Issa CG, Yilmaz M, Daver GN, Pemmaraju N, Masarova L, Ravandi F, Jain N, Deen W, Loiselle C, Waller L, Banks G, Harris R. Low-intensity chemotherapy (mini-HCVD) and ponatinib followed by blinatumomab (blina) and ponatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): A phase II study. Journal of Clinical Oncology 41(Supplement 16):e19028, 2023. e-Pub 2023.
7. Bewersdorf JP, Verstovsek S, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal KR, Bose P. A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
8. Bewersdorf JP, Verstovsek S, Derkach A, Masarova L Pemmaraju N, Stein E, Mauro M, Rampal KR, Bose P. A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
9. Mesa AR, Palandri F, Verstovsek S, Masarova L, Harrison C, Mazerolle F, Gorsh B, M'Hari M, Wang Z, Ellis EC, Deheshi S, Kawashima J, Maltzahn VR, Regnault A. Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2). Journal of Clinical Oncology 41(Supplement 16), 2023. e-Pub 2023.
10. Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-354 Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S334, 2022. e-Pub 2022. PMID: 36164003.
11. Masarova L, Bose P, Pemmaraju N, Kantarjian H, Estrov Z, Verstovsek S. MPN-355 Patients With Prefibrotic Myelofibrosis and Inferior Outcome, a Single-Center Analysis. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S334-S335, 2022. e-Pub 2022. PMID: 36164004.
12. Masarova L, Bose P, Pemmaraju N, Chifotides H, Zhou L, Estrov Z, Kantarjian H, Verstovsek S. Outcome of Patients with Prefibrotic Myelofibrosis from a Large Academic Center. EHA Library, 2022. e-Pub 2022.
13. Masarova L, Bose P, Pemmaraju N, Chifotides HT, Zhou L, Estrov Z, Kantarjian H, Verstovsek S. Characteristics of patients with myelofibrosis on ruxolitinib for three or more years. Journal of Clinical Oncology 40(16_suppl):e19082-e19082, 2022. e-Pub 2022.
14. Nguyen D, Jabbour JE, Short JN, Issa CG, Yilmaz M, Daver N, Pemmaraju N, Chien SK, Masarova L, Ravandi F, Jain N, Deen W, Zhao M, Loiselle C, Waller L, Banks G, Garris R, Kantarjian H. . A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood 140(Supplement 1):6127-6129, 2022. e-Pub 2022.
15. Abuasab T, Verstovsek S, Borthakur G, Kanagal-Shamanna R, Patel K, Takahashi K, Masarova L, Bose P, Villarreal J, Pierce AS, Montalban-Bravo G, Garcia-Manero G, Short JN, DiNardo DC, Daver N, Ravandi F, Kantarjian H, Yilmaz M. The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms. Blood 140(Supplement 1):8954-8956, 2022. e-Pub 2022.
16. Abuasab T, Garcia-Manero G, Short JN, Alvarado Y, Issa CG, Islam R, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau MS, Jabbour JE, Pemmaraju N, Montalban-Bravo G, Pierce AS, DiNardo DC, Kadia MT, Daver N, Konopleva M, Kantarjian H, Ravandi F. Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy. Blood 140(Supplement 1):3324-3326, 2022. e-Pub 2022.
17. Senapati J, Short NJ, Alvarado Y, Burger AJ, Jain N, Konopleva M, Ravandi F, DiNardo DC, Masarova LMasarova L, Sasaki K, Thompson AP, Ferrajoli A, Jacob J, Mayor E, Milton A, Loiselle C, Garris R, Kantarjian H, Jabbour EJ. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood 140(Supplement 1):3253-3255, 2022. e-Pub 2022.
18. Bataller A, Kanagal-Shamanna R, Chien SK, Montalban-Bravo G, Kadia MT, Ravandi F, DiNardo DC, Daver N, Short JN, Borthakur G, Jabbour JE, Hammond D, Masarova L, Ganan-Gomez I, Adema V, Kantarjian H, Garcia-Manero G, Sasaki K. Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome. Blood 140(Supplement 1):9793-9795, 2022. e-Pub 2022.
19. Senapati J, Huante Almanza E, Kadia MT, Montalban-Bravo G, Faderl S, Sasaki K, Short JN, Daver N, DiNardo DC, Masarova L, Ferrajoli A, Jabbour JE, Borthakur G, Al Azzawi H, Konopleva M, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, Alvarado Y. Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 140(Supplement 1):9050-9053, 2022. e-Pub 2022.
20. Baker R, Baskar J, Charlton B, Hobbs SG, Jarolimek W, S-E L, Masarova L, A-M W. Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis. Blood 140(Supplement 1):3947-3948, 2022. e-Pub 2022.
21. Gener-Ricos G, Haddad GF, Sasaki K, Issa CG, Skinner J, Takahashi K, Masarova L, Burger AJ, Borthakur G, Bose B, Garcia-Manero G, Jabbour JE, Kantarjian H. Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood 140(Supplement 1):1493-1494, 2022. e-Pub 2022.
22. Reville PK, Kantarjian H, Borthakur G, Yilmaz M, Daver N, Short N, DiNardo DC, Kornblau MS, Pemmaraju N, Jain N, Alvarado Y, Bose P, Jabbour JE, Chien SK, Abbas AH, Masarova L, Wang AS, Tidwell SR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia MT. Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Blood 140(Supplement 1):1702-1704, 2022. e-Pub 2022.
23. Bewersdorf JP, Verstovsek S, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal KR, Bose P. Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 140(Supplement 1):6844-6846, 2022. e-Pub 2022.
24. Desikan SP, Konopleva M, Takahashi M, Lachowiez AC, Loghavi S, L-C X, Kadia MT, Daver N, Short N, Sasaki K, Borthakur G, Issa CG, Maiti A, Chien SK, Alvarado Y, Montalban-Bravo G, Masarova L, Yilmaz M, Andreeff M, Jabbour JE, Garcia-Manero G, Kornblau MS, Ravandi F, H, Kantarjian, DiNardo DC. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. Blood 140(Supplement 1):534-536, 2022. e-Pub 2022.
25. Masarova L, Bose P, Pemmaraju N, Richie MA, Borthakur G, Estrov EZ, Kantarjian H, Patel PK, Verstovsek S. Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years. Blood 140(Supplement 1):9683-9684, 2022. e-Pub 2022.
26. Maiti A, DiNardo DC, Ohanian M, Pemmaraju N, Daver N, Borthakur G, Ravandi F, Issa CG, Garcia-Manero G, Jain N, Kadia MT, Masarova L, Wierda GW, Yilmaz M, Alvarado Y, Jabbour JE, Short JN, Takahashi K, Loghavi S, Patel PK, Montalbano K, Pierce AS, Bivins AC, Mehta SR, Alatrash G, Popat RU, Kebriaei P, Oran B, Shpall JE, Champlin ER, Kantarjian H, Konopleva M. Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial. Blood 140(Supplement 1):7725-7728, 2022. e-Pub 2022.
27. Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov Z, Kantarjian H, Verstovsek S. Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils. , 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, Atlanta, GA, 2021. e-Pub 2021.
28. Masarova L, Bose P, Pemmaraju N, Zhou L, Pierce SA, Estrov Z, Kantarjian H, Verstovsek S. Clinical Features Associated with Long-Term Ruxolitinib Exposure in Myelofibrosis and Predictive Role of Neutrophils. Blood 138(Suppl 1), 2021. e-Pub 2021.
29. Pemmaraju N, Bhalla NK, Daver N, Wilson RN, Fiskus CW, Ravandi F, Garcia-Manero G, Kadia MT, DiNardo DC, Jabbour JE, Burger AJ, Short JN, Alvarado Y, Jain N, Masarova L, Verstovsek S, Issa CG, Qiao W, Khoury DJ, Pierce AS, Miller D, Konopleva M, Kantarjian H, Borthakur G. Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood 138(Supplement 1):3421, 2021. e-Pub 2021.
30. Venugopal S, Issa CG, Konopleva M, DiNardo DC, Borthakur G, Jabbour JE, Pemmaraju N, Yilmaz M, Short JN, Maiti A, Sasaki K, Masarova L, Pierce AS, Takahashi K, Tang G, Loghavi S, Andreeff M, Bhalla NK, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood 138(Supplement 1):2287, 2021. e-Pub 2021.
31. Mohamed FS, Assi R, Ning J, Xiao L, Jabbour JR, Pemmaraju N, Kadia MT, Jain N, DiNardo CD, Yilmaz M, Maiti A, Issa CG, Short JN, Bose P, Masarova L, Garcia-Manero G, Ravandi F, Konopleva M, Kantarjian H, Daver N. Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood 138(Supplement 1):1213, 2021. e-Pub 2021.
32. Lachowiez C, DiNardo DC, Takahashi K, Loghavi S, L-C X, Kadia MT, Daver N, Adeoti M, Short JN, Sasaki K, Wang AS, Borthakur G, Issa CG, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau MS, Ravandi F, Jabbour JE, Konopleva M, Kantarjian H. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood 138(Supplement 1):701, 2021. e-Pub 2021.
33. Bose P, Manshouri T, Bledsoe DS, Jain N, Masarova L, Pemmaraju N, Hall N, Richie MA, Wang X, Kantarjian H, Estrov EZ, Verstovsek S. A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis. Blood 138(Supplement 1):3635, 2021. e-Pub 2021.
34. Bose P, Masarova L, Pemmaraju N, Bledsoe DS, Daver N, Jabbour JE, Kadia MT, Estrov EZ, Kornblau MS, Andreeff M, Cortes EJ, Jain N, Borthakur G, Alvarado Y, Huynh-Lu J, Nguyen-Cao MM, Richie MA, Dobbins HM, McCrackin AS, Zhou L, Pierce AS, Wang X, Pike MA, Garcia-Manero G, Kantarjian H, Verstovsek S. Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Blood 138(Supplement 1):144, 2021. e-Pub 2021.
35. Short JN, Kantarjian H, Alvarado Y, Burger AJ, Jain N, Konopleva M, Ravandi F, DiNardo CD, Masarova L, Sasaki K, Thompson AF, Ferrajoli A, Jacob J, Milton A, Garris R, Jabbour JE. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood 138(Supplement 1):2299, 2021. e-Pub 2021.
36. Maiti A, DiNardo CD, Rausch RC, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver D, Issa CG, Borthakur G, Ravandi F, Alvarado Y, Kadia MT, Shot JE, Jabbour JE, Montalban-Bravo G, Jain N, Kornblau MS, Masarova L, Wierda GW, Sasaki K, Takahashi K, Yilmaz M, Burger AJ, Estrov EZ, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson AP, Montalbano K, Vaughan K, Bivins AC, Pierce AS, Qiao W, Ning J, Welch SG, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138(Supplement 1):1270, 2021. e-Pub 2021.
37. Jain N, Ferrajoli A, Yilmaz M, Thompson AP, Konopleva M, Green RM, Sampath D, Neelapu SS, Takahashi K, Masarova L, Burger AJ, Kanagal-Shamanna R, Khoury DJ, Garg N, Su X, Wang X, Patel H, Ayala A, Kantarjian H, Keating JM, Wierda GW. Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 138(Supplement 1):2626, 2021. e-Pub 2021.
38. Yilmaz M, Muftuoglu M, Kantarjian H, DiNardo DC, Kadia MT, Konopleva M, Borthakur G, Pemmaraju N, Short JN, Alvarado Y, Maiti A, Masarova L, Montalban-Bravo G, Jurisprudencia A, Pike MA, Loghavi S, Patel K, Tang G, Matthews AJ, Kornblau MS, Jabbour JE, Garcia-Manero G, Ruvolo V, Ravandi F, Andreeff M, Daver N. Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood 138(Supplement 1):370, 2021. e-Pub 2021.
39. Maiti A, DiNardo CD, Rausch RC, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver D, Issa CG, Borthakur G, Ravandi F, Alvarado Y, Kadia MT, Jabbour JE, Short JN, Montalban-Bravo G, Jain N, Kornblau MS, Masarova L, Wierda GW, Sasaki K, Takahashi K, Yilmaz M, Burger AJ, Estrov EZ, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson AP, Montalbano K, Vaughan K, Bivins AC, Pierce AS, Qiao W, Ning J, Welch SG, Kantarjian H, Konopleva M. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood 138(Supplement 1):694, 2021. e-Pub 2021.
40. Bazinet A, Jabbour JE, Kantarjian H, Chien SK, DiNardo DK, Ohanian M, Daver N, Kanagal-Shamanna R, Kadia MT, Takahashi K, Masarova L, Short JN, Alvarado Y, Thompson AP, Montalban-Bravo G, Yilmaz M, Ravandi F, Kornblau MS, Pemmaraju N, Schneider H, Mirabella B, Naqvi K, Garcia-Manero G. A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood 138(Supplement 1):535, 2021. e-Pub 2021.
41. Lachowiez C, Borthakur G, Loghavi S, Zeng Z, Kadia T, Masarova L, Takahashi K, Tippett G, Naqvi K, Bose P, Jabbour E, Ravandi F, Daver N, Garcia-Manero G, Stoilova B, Vyas P, Kantarjian H, Konopleva M, Dinardo C. Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
42. Guerra V, Kantarjian H, Cortes J, Garcia-Manero G, Masarova L, Pemmaraju N, Jabbour E, Kadia T, DiNardo C, Zhou L, Pierce S, Borthakur G, Wierda W, Ferrajoli A, Sasaki K, Takahashi K, Naqvi K, Alvarado Y, Ohanian M, Jain N, Bose P, Ravandi F, Konopleva M, Estrov Z, Verstovsek S, Daver N. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 134(Suppl 1), 2019. e-Pub 2019.
43. Daver N, Garcia-Manero G, Konopleva M, Alfayez M, Pemmaraju N, Kadia T, DiNardo C, Cortes J, Ravandi F, Abbas H, Basu S, Jabbour E, Pierce S, Estrov Z, Takahashi K, Ning J, Kornblau S, Sasaki K, Masarova L, Flores W, Allison J, Sharma P, Kantarjian H. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood 134(Suppl 1), 2019. e-Pub 2019.
44. Fiskus W, Mill C, Karkhanis V, Lara B, Bose P, Masarova L, Kadia T, Shao N, Bhalla I, Maher J, Khoury J, Sharma S, Manshouri T, Verstovsek S, Bhalla K. Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells. Blood 134(Suppl 1), 2019. e-Pub 2019.
45. Richard-Carpentier G, DeZern A, Takahashi K, Konopleva M, Loghavi S, Masarova L, Alvarado Y, Ravandi F, Montalban Bravo G, Naqvi K, Sasaki K, Delumpa R, Kwari M, Sekeres M, Nazha A, Roboz G, Kantarjian H, Garcia-Manero G, DiNardo C. Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Blood 134(Suppl 1), 2019. e-Pub 2019.
46. Aboudalle I, Konopleva M, Kadia T, Naqvi K, Vaughan K, Kurt M, Cavazos A, Pierce S, Takahashi K, Masarova L, Yilmaz M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Cortes J, Kantarjian H, DiNardo C. A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood 134(Suppl 1), 2019. e-Pub 2019.
47. Maiti A, DiNardo C, Rausch C, Cortes J, Pemmaraju N, Daver N, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Benton C, Kadia T, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Rytting M, Thompson P, Wang S, Konoplev S, Chen S, Goswami M, Maduike R, Guerrero J, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale S, Tse S, Thomas R, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 134(Suppl 1), 2019. e-Pub 2019.
48. Maiti A, Rausch C, Cortes J, Pemmaraju N, Daver N, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Benton C, Kadia T, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Rytting M, Thompson P, Wang S, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero J, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale S, Tse S, Thomas R, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Kantarjian H, Konopleva M, DiNardo C. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 134(Suppl 1), 2019. e-Pub 2019.
49. Maiti A, Rausch C, Cortes J, Pemmaraju N, Daver N, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Benton C, Kadia T, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Rytting M, Thompson P, Wang S, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero J, Zhang Q, Cavazos A, Ma H, Bivins C, Wade A, Adewale S, Tse S, Thomas R, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Patel K, Kantarjian H, Konopleva M, DiNardo C. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 134(Suppl 1), 2019. e-Pub 2019.
50. Masarova L, Verstovsek S, Bose P, Pemmaraju N, Cortes J, Jabbour E, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Kadia T, DiNardo C, Ravandi F, Konopleva M, Naqvi K, Sasaki K, Estrov Z, Garcia-Manero G, Bueso-Ramos C, Kantarjian H, Daver N. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood 134(Suppl 1), 2019. e-Pub 2019.
51. Alfayez M, Kadia T, Konopleva M, Ravandi F, Jabbour E, Garcia-Manero G, Pierce S, Yilmaz M, Short N, Cortes J, Shoukier M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian H, DiNardo C, Daver N. Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). Blood 134(Suppl 1), 2019. e-Pub 2019.
52. Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. European Hematology Association, 2018. e-Pub 2018.
53. Romano A, Palandri F, Masarova L, Bonifacio M, Polverelli N, Elli E, Iurlo A, Bergamaschi M, Benevolo G, Tieghi A, Sgherza N, Cavazzini F, Isidori A, Binotto G, Bosi C, Crugnola M, Catani L, Scaffidi L, Cattaneo D, Vitolo U, Cuneo A, Semenzato G, Aversa F, Cavo M, Vianelli N, Bartoletti D, Scalise L, Palumbo G, Di Raimondo F, Verstovsek S. Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. Blood Suppl 1(132):4303, 2018. e-Pub 2018.
54. Maiti A, DiNardo C, Cortes J, Borthakur G, Pemmaraju N, Benton C, Kadia T, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short N, Daver N, Sasaki K, Ohanian M, Garcia-Manero G, Thompson P, Kornblau S, Masarova L, Jain N, Jabbour E, Andreeff M, Maduike R, Guerrero J, Zhang Q, Cavazos A, Ma H, Rausch C, Bivins C, Vaughan K, Pierce S, Ning J, Qiao W, Welch J, Kantarjian H, Konopleva M. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood Suppl 1(132):286, 2018. e-Pub 2018.
55. Masarova L, Verstovsek S, Cortes J, Pemmaraju N, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Daver N. Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood 132(Suppl 1):352, 2018. e-Pub 2018.
56. Gowin K, Ballen K, Ahn K, Hu Z, Liu Y, Masarova L, Verstovsek S, Coakley M, Jain T, Kuykendall A, Komrokji R, Wadleigh M, Patches S, Arcasoy M, Green M, Kandarpa M, Talpaz M, Ali H, Gupta V, Devlin R, Michaelis L, Hobbs G, Stein B, Pariser A, Gerds A, Kuber K, Rampal R, Alyea III E, Popat U, Sobecks R, Scott B, Mesa R, Saber W. Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score. Blood 132(Suppl 1):4288, 2018. e-Pub 2018.
57. Santos F, Getta B, Masarova L, Famulare C, Schulman J, Puga R, de Melo Alves Paiva R, Hamerschlak N, Kantarjian H, Levine R, Campregher P, Rampal R, Verstovsek S. Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia /Polycythemia Vera Myelofibrosis. Blood 132(Suppl 1):1756, 2018. e-Pub 2018.
58. Masarova L, Cortes J, Patel K, O'Brien S, Nogueras González G, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia T, Ravandi F, Borthakur G, Dellasala S, Jabbour E, Kantarjian H. Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. Blood 132(Suppl 1):3011, 2018. e-Pub 2018.
59. Saenz D, Fiskus W, Manshouri T, Saenz D, Soldi R, Sun B, Mill C, Nowak A, Kornblau S, Bose P, Kadia T, DiNardo C, Masarova L, Horrigan S, Khoury J, Sharma S, Verstovsek S, Bhalla K. Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis. Blood 132(Suppl 1):177, 2018. e-Pub 2018.
60. Rausch C, Paul S, Montalban Bravo G, Jabbour E, Daver N, Alvarado Y, DiNardo C, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Kornblau S, Cortes J, Kadia T, Konopleva M, Ohanian M, Pierce S, Gasior Y, Benton C, Jain N, Takahashi K, Masarova L, Andreeff M, Estrov Z, Kantarjian H, Garcia-Manero G. Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood 132(Suppl 1):4367, 2018. e-Pub 2018.
61. Bose P, McCue D, Wiederhold N, Kadia T, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson P, Pemmaraju N, Daver N, Burger J, Cortes J, Garcia-Manero G, Verstovsek S, Konopleva M, Jain N, DiNardo C, Alvarado Y, Naqvi K, Kornblau S, Ferrajoli A, Wierda WEstrov Z, Benton C, Masarova L, Montalban-Bravo G, Sasaki K, Rausch C, Marx K, Qiao W, Huang X, Bivins C, Pierce S, Kantarjian H, Kontoyiannis D. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132(Suppl 1):2674, 2018. e-Pub 2018.
62. Masarova L, Daver N, Kadia T, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia - Final Results of a Prospective Phase 2 Study. American Society of Hematology. Blood 132(Suppl 1):1764, 2018. e-Pub 2018.
63. Santos F, Getta B, Masarova L, Famulare C, Schulman J, Santos Datoguia T, Goncalves G, Hamerschlak N, Kantarjian H, Levine R, Campregher P, Rampal R, Verstovsek S. A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis. Blood 132(Suppl 1):1757, 2018. e-Pub 2018.
64. Masarova L, Bose P, Pemmaraju N, Estrov Z, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Evaluation of Cytogenetic Stratifications in Myelofibrosis. Blood 132(Suppl 1):1763, 2018. e-Pub 2018.
65. Masarova L, Bose P, Newberry K, Abou Zahr A, Cortes J, Kantarjian H, Verstovsek S. Correlation between blast percentage in myelofibrosis and outcomes: a single-center experience. American Society of Clinical Oncology, 2017. e-Pub 2017.
66. Boddu P, Mansurov A, Masarova L, Bose P, Patel K, Estrov Z, Kantarjian H, Verstovsek S. Non-Driver Mutations and Gene Sequence Variants Identified By Targeted Deep Sequencing in Polycythemia Vera and Essential Thrombocythemia. American Society of Hematology:4183, 2017. e-Pub 2017.
67. Masarova L, Cortes J, Pemmaraju N, Jabbour E, Bose P, Ohanian M, Zhou L, Pierce S, Gergis R, Borthakur G, Estrov Z, Garcia-Manero G, Kantarjian H, Verstovsek S, Daver N. Phase 2 study of Ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis. American Society of Clinical Oncology:7063, 2017. e-Pub 2017.
68. Masarova L, Patel K, Mallampathi S, Duose YD, Newberry JK, Cortes J, Estrov Z, Kantarjian H, Luthra R, Verstovsek S. Correlation of Mutational Profile and Response in Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Pegylated Interferon Alfa 2a As Part of a Prospective Phase II Study. American Society of Hematology:1640, 2017. e-Pub 2017.
69. Masarova L, Bose P, Cortes J, Kantarjian H, Verstovsek S. Do we need to re-define accelerated phase of myelofibrosis? Correlation between blast percentage in myelofibrosis and outcomes. Society of Hematologic Oncology:131, 2017. e-Pub 2017.
70. Masarova L, Kantarjian H, Verstovsek S. Validation of The Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. International Association for Comparative Research on Leukemia and Related Diseases:31, 2017. e-Pub 2017.
71. Masarova L, Bose P, Pemmaraju N, Daver N, Cortes J, Estrov Z, Kantarjian H, Verstovsek S. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. American Society of Hematology:4205, 2017. e-Pub 2017.
72. Masarova L, Kantarjian H, Verstovsek S. Elevated peripheral blood (4-9%) and bone marrow blasts (5-9%) are associated with poor prognosis in patients with primary myelofibrosis as well as post-essential thrombocythemia and post-polycythemia vera myelofibrosis. International Association for Comparative Research on Leukemia and Related Diseases:131, 2017. e-Pub 2017.
73. Masarova L, Bose P, Daver N, Newberry K, Cortes J, Garcia-Manero G, Kantarjian H, Verstovsek S. Clinical characteristics of patients with primary or post-polycythemia vera/post-essential thrombocytopenia myelofibrosis and deletion 13q. Society of Hematologic Oncology:114, 2016. e-Pub 2016.
74. Masarova L, Bose P, Daver N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Allogeneic stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy. American Society of Hematology:4687, 2016. e-Pub 2016.
75. Masarova L, Bose P, Pemmaraju N, Daver N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Does Therapy- Related Myelofibrosis Exist? Analysis of 1100 Myelofibrosis Cases from a Single Institution. J Clinical Oncology:34, 2016. e-Pub 2016.
76. Masarova L, Newberry K, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Does occurrence of other malignancy after essential thrombocythemia (ET) and polycythemia vera (PV) influence their rate of transformation to myelofibrosis (MF)?. Society of Hematologic Oncology:116, 2016. e-Pub 2016.
77. Masarova L, Verstovsek S. Co-occurrence of lymphoproliferative neoplasm and myelofibrosis. Pan-Pacific Lymphoma Conference:61, 2016. e-Pub 2016.
78. Alhuraiji A, Masarova L, Bose P, Daver N, Cortes J, Pierce S, Kantarjian H, Verstovsek S. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: a single-center experience in 1100 myelofibrosis patients. J Clinical Oncology, 2016. e-Pub 2016.
79. Masarova L, Yin C C, Cortes J, Konopleva M, Borthakur G, Newberry K, Kantarjian H, Bueso-Ramos C, Verstovsek S. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV). American Society of Hematology:4266, 2016. e-Pub 2016.
80. Masarova L, Bose P, Pemmaraju N, Newberry K, Bueso-Ramos C, Cortes J, Kantarjian H. Clinical associations of cytogenetic abnormalities in patients with primary and post-essential thrombocythemia / post-polycythemia vera myelofibrosis. American Society of Hematology:4265, 2016. e-Pub 2016.
81. Masarova L, Bose P, Daver N, Newberry K, Cortes J, Kantarjian H, Verstovsek S. Cytogenetic risk stratification in primary versus post-essential thrombocythemia and post-polycythemia vera myelofibrosis. American Society of Hematology:4250, 2016. e-Pub 2016.
82. Masarova L, Bose P, Newberry K, Cortes J, Garcia-Manero G, Kantarjian H, Verstovsek S. Therapy-Related Myelofibrosis does not appear to exist. Society of Hematologic Oncology:115, 2015. e-Pub 2015.
83. Masarova L, Newberry K, Daver N, Pemmaraju N, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Clinical relevance of other malignancies in patients with myelofibrosis. The 8th International Congress on Myeloproliferative Neoplasms, Myelodysplasia and Chronic Myeloid Leukemia:102, 2015. e-Pub 2015.
84. Masarova L, Daver N, Pemmaraju N, Bose P, Pierce S, Manshouri T, Cortes J, Kantarjian H, Verstovsek S. Do patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis?. American Society of Hematology:4069, 2015. e-Pub 2015.
85. Rivera D, Kadia MT, Montalban-Bravo G, Faderl S, Sasaki K, Short JN, Daver N, DiNardo DC, Masarova L, Ferrajoli A, Jabbour JE, Borthakur G, Al Azzawi H, Konopleva M, Gacria-Manero G, Adreeff M, Kantarjian H, Ravandi F, Asvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 2021 138(Supplement 1):2323.

Book Chapters

1. Masarova, L, Verstovsek, S. Interferons in Myeloproliferative Neoplasms, 559-565, 2023.
2. Verstovsek S, Bose P, Masarova L, Amin H. Philadelphia chromosome negative myeloproliferative neoplasms. In: The MD Anderson Manual of Medical Oncology. 4th edition, 2023.
3. Masarova L, Verstovsek S. Interferons in Myeloproliferative Neoplasms. In: Pathogenesis and Treatment of Leukemia. Springer publishing, 2023.
4. Drgona, L, Masarova, L. CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4, 89-112, 2022.
5. Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. In: Adv Exp Med Biol, 97-116, 2018.
6. Reckova M, Ballova V, Drgona L, Masarova L, Mego M, et al. Biological therapy in clinical oncology. In: Selected Chapters in Medical Oncology. First. Rowex, Bratislava, 2014.

Letters to the Editor

1. Swaminathan, M, DiNardo, C, Maiti, A, Pemmaraju, N, Ohanian, M, Daver, NG, Garcia-Manero, G, Issa, GC, Borthakur, G, Ravandi-Kashani, F, Montalban Bravo, G, Kadia, TM, Alvarado, Y, Jabbour, EJ, Short, NJ, Wierda, WG, Jain, N, Kornblau, SM, Masarova, L, Pierce, S, Qiao, W, Ning, J, Kantarjian, HM, Konopleva, M. VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome. Blood cancer journal 15, 2025.
2. Jen, WY, Jabbour, EJ, Short, NJ, Issa, GC, Haddad, FG, Jain, N, Pemmaraju, N, Daver, N, Masarova, L, Borthakur, G, Chien, KS, Garris, R, Kantarjian, H. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. American journal of hematology 99: 2229-2232, 2024.
3. Bose P, Masarova L, Pemmaraju N, Bledsoe SD, Daver NG, Jabbour EJ, Kadia TM, Estrov Z, Kornblau SM, Andreeff M, Jain N, Cortes JE, Borthakur G, Alvarado Y, Richie MA, Dobbins MH, McCrackin SA, Zhou L, Pierce SA, Wang X, Pike AM, Garcia-Manero G, Kantarjian HM, Verstovsek S. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica 109: 2660-2664, 2024.
4. Abuasab T, Borthakur G, Kanagal-Shamanna R, Masarova L, Patel K, Takahashi K, Bose P, Villarreal J, Pierce S, Kadia T, Garcia-Manero G, Short NJ, DiNardo C, Daver N, Ravandi F, Kantarjian H, Verstovsek S, Yilmaz M. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol 99: 1434-1436, 2024.
5. Fiskus W, Manshouri T, Birdwell C, Mill CP, Masarova L, Bose P, Kadia TM, Daver N, DiNardo CD, Borthakur G, Khoury JD, Verstovsek S, Bhalla KN. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J 12: 23, 2022.
6. Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Am J Hematol 96: E229-E232, 2021.
7. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193: 1004-1008, 2021.
8. Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106: 894-898, 2021.
9. Verstovsek S, Subbiah V, Masarova L, Yin CC, Tang G, Manshouri T, Asatiani E, Daver NG. Treatment of The Myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 Inhibitor. Ann Oncol 29: 1880-1882.
10. Masarova L, Wang W, Newberry KJ, Kantarjian H, Verstovsek S. Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis. Blood 128: 877-80, 2016.